Comparison · NCT03640312-9eac7516
QUARTET LDQT vs Candesartan: Medication Adherence
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. QUARTET LDQT vs Candesartan: Medication Adherence. Trial comparisons, record NCT03640312-9eac7516. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03640312-9eac7516
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.656 | 0.483 | 0.796 | wilson | |
| Risk in group 2 | 0.7 | 0.521 | 0.833 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0437 | -0.262 | 0.183 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.938 | 0.665 | 1.32 | log | |
| Odds ratio, group 1 over group 2 | 0.818 | 0.281 | 2.38 | log | |
| Number needed to treat, for one fewer participant with the outcome on QUARTET LDQT than on Candesartan | 22.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | QUARTET LDQT | Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at ¼ standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.~QUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks. | 21 | 32 | OG000 |
| Group 2 | Candesartan | Patients randomized to the comparison arm took a once daily 8mg candesartan.~Candesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks. | 21 | 30 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Medication Adherence
- Description
- Medication adherence defined by objective pill counts
- Time frame
- 12 weeks
- Population
Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension
- NCT number
- NCT03640312
- Phases
- PHASE2
- Conditions
- Hypertension
- Interventions
- QUARTET LDQT, Candesartan
- Lead sponsor
- Washington University School of Medicine
- Results first posted
- 2023-09-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03640312?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03640312-9eac7516